Literature DB >> 7876859

Treatment of chronic limb spasticity with botulinum toxin A.

J W Dunne1, N Heye, S L Dunne.   

Abstract

The purpose of this open study was to find out whether botulinum toxin A (BTX-A) relieves the signs and symptoms of chronic limb spasticity. The study comprised 40 patients, aged 12-82 years, with moderate to severe spasticity of the upper (13) or lower limbs (27) refractory to conventional physical and medical treatments. Outcome measures were clinical and blinded videotape assessments of spasticity and motor function. Electromyography guided BTX-A injections were given in one or two sessions at total doses averaging 175 U in the upper limb (range 70-270 U) and 221 U in the lower limb (range 100-500 U). Thirty four patients (85%) derived worthwhile benefit, with improved limb posture and increased range of passive motion in 31, pain reduction in 28 of 31 with pain, and improved function in 16. Side effects were limited to local and usually mild discomfort from the injections (19), symptomatic local weakness (one), and local infection (one). Preliminary experience indicates that BTX-A is a promising adjunctive treatment for selected patients with spasticity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876859      PMCID: PMC1073325          DOI: 10.1136/jnnp.58.2.232

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  Botulinum toxin in treating spasticity.

Authors:  T K Das; D M Park
Journal:  Br J Clin Pract       Date:  1989-11

2.  Evaluation of functional capacity after stroke as a basis for active intervention. Presentation of a modified chart for motor capacity assessment and its reliability.

Authors:  B Lindmark; E Hamrin
Journal:  Scand J Rehabil Med       Date:  1988

3.  Drug therapy: spasticity (first of two parts).

Authors:  R R Young; P J Delwaide
Journal:  N Engl J Med       Date:  1981-01-01       Impact factor: 91.245

4.  Reliability of goniometric measurements.

Authors:  D C Boone; S P Azen; C M Lin; C Spence; C Baron; L Lee
Journal:  Phys Ther       Date:  1978-11

5.  Evaluation of functional capacity after stroke as a basis for active intervention. Validation of a modified chart for motor capacity assessment.

Authors:  B Lindmark; E Hamrin
Journal:  Scand J Rehabil Med       Date:  1988

6.  Quantifying how location and dose of botulinum toxin injections affect muscle paralysis.

Authors:  C M Shaari; I Sanders
Journal:  Muscle Nerve       Date:  1993-09       Impact factor: 3.217

7.  Local botulinum toxin in the treatment of spastic drop foot.

Authors:  R Dengler; U Neyer; K Wohlfarth; U Bettig; H H Janzik
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

8.  Management of cerebral palsy with botulinum-A toxin: preliminary investigation.

Authors:  L A Koman; J F Mooney; B Smith; A Goodman; T Mulvaney
Journal:  J Pediatr Orthop       Date:  1993 Jul-Aug       Impact factor: 2.324

  8 in total
  20 in total

Review 1.  [Use of botulinum toxin the the treatment of muscle pain].

Authors:  R Benecke; D Dressler; E Kunesch; T Probst
Journal:  Schmerz       Date:  2003-12       Impact factor: 1.107

2.  [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].

Authors:  J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

3.  Anatomic localization of motor entry points and intramuscular nerve endings in the hamstring muscles.

Authors:  X C An; J H Lee; S Im; M S Lee; K Hwang; H W Kim; Seung-Ho Han
Journal:  Surg Radiol Anat       Date:  2010-01-10       Impact factor: 1.246

4.  Evaluating the role of botulinum toxin in the management of focal hypertonia in adults.

Authors:  D Richardson; G Sheean; D Werring; M Desai; S Edwards; R Greenwood; A Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-10       Impact factor: 10.154

Review 5.  Pure hereditary spastic paraplegia.

Authors:  E Reid
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

6.  Treatment of chronic limb spasticity with botulinum toxin A.

Authors:  B B Bhakta; J A Cozens; M A Chamberlain; J M Bamford
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

Review 7.  Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology.

Authors:  A Berardelli; G Abbruzzese; L Bertolasi; G Cantarella; F Carella; A Currà; D De Grandis; G DeFazio; G Galardi; P Girlanda; P Livrea; N Modugno; A Priori; G Ruoppolo; L Vacca; M Manfredi
Journal:  Ital J Neurol Sci       Date:  1997-10

8.  Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial.

Authors:  B B Bhakta; J A Cozens; M A Chamberlain; J M Bamford
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

Review 9.  Botulinum toxin treatment of adult spasticity : a benefit-risk assessment.

Authors:  Geoffrey Sheean
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

10.  A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients.

Authors:  P Burbaud; L Wiart; J L Dubos; E Gaujard; X Debelleix; P A Joseph; J M Mazaux; B Bioulac; M Barat; A Lagueny
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.